Xilio Therapeutics (XLO) Non-cash Items (2021 - 2026)

Xilio Therapeutics has disclosed Non-cash Items across 6 years of filings, most recently posting $726042.0 for Q1 2026.

• Non-cash Items for Q1 2026 came in at $726042.0, down 83.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $726042.0 (down 83.97% YoY), and the FY2025 annual result was $27000.0, down 90.43% from the prior year.
• Non-cash Items came in at $726042.0 for Q1 2026 at Xilio Therapeutics, up from $27000.0 in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $12.5 million in Q4 2023 to a low of $27000.0 in Q4 2025.
• The 5-year median for Non-cash Items is $1.4 million (2022), against an average of $2.3 million.
• Across the five-year window, Non-cash Items tumbled 99.71% in 2022 and surged 13944.94% in 2023, its largest moves.
• Xilio Therapeutics' Non-cash Items stood at $89000.0 in 2022, then soared by 13944.94% to $12.5 million in 2023, then sank by 97.74% to $282000.0 in 2024, then plunged by 90.43% to $27000.0 in 2025, then surged by 2589.04% to $726042.0 in 2026.
• The last three Non-cash Items figures came in at $726042.0 (Q1 2026), $27000.0 (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.